Carbamazepine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Leucht, Stefan ^a   Helfer, Bartosz ^a   Dold, Markus ^b   Kissling, Werner ^b   Mcgrath, John ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; TRANQUILIZER;

AGGRESSION; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EEG ABNORMALITY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MENTAL HEALTH; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PROCEDURES; RECURRENT DISEASE;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; COMBINED MODALITY THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA;

EID: 84907277710     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001258.pub3     Document Type: Review

References (177)

1. Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE. Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry 1991;48(1):69-72.
2. Dose M. Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991.
3. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research 1987;22(4):303-10.
4. Dose M, Emrich HM. Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research 1988;1(2, 3):207-8.
5. Dose M, Emrich HM. Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift 1990;132 (suppl 1):87-90.
6. Dose M, Garcia D, Weber M, Yassouridis A, Emrich HM. Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry 1989;22(5):195.
7. Hesslinger B, Klose P, Normann C, Langosch JM, Berger M, Walden J. Carbamazepine co-treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie 1998;66(4):145-50.
8. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology 1999;19(4):310-5.
9. Normann C, Klose P, Hesslinger B, Langosch JM, Berger M, Walden J. Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co-medication: a clinical trial. Pharmacopsychiatry 1997;30:204.
10. Walden J, Hesslinger B, Normann C, Langosch J, Berger M. Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland. 1998.
11. Estorges JP, Llorca PM, Lancon C, Bougerol T, Scotto JC. Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale 1991;17(4):307.
12. Llorca PM, Wolf MA, Lancon C, Bougerol T. Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale 1993;19(5):565-71.
13. Mair M, Tschapeller I, Schubert H. Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie. In: Schonbeck G, Platz T editor(s). Schizophrenie erkennen, verstehen, behandeln. Beiträge aus Theorie und Praxis. Wien: Springer Verlag, 1990:77-92.
14. Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, Guajardo FI. Carbamazepine: An effective adjunct treatment for schizophrenia [La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1992;20(1):11-6.
15. Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, Ibarra IG. Carbamazepine: An efficacious adjuvant treatment in schizophrenia [La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1989;17(4):245-50.
16. Nachshoni T, Levin Y, Levy A, Kritz A. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry 1994;35(1):22-6.
17. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry 1983;44(9):326-31.
18. Neppe VM. Carbamazepine in the psychiatric patient. Lancet 1982;2(8293):334.
19. Neppe VM. Non-responsive psychosis - a biochemical difference?. South African Medical Journal 1983;63(21):797-8.
20. Meszaros K, Simhandl C, Denk E, Liechtenstein A, Topitz A, Thau K. A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA 1996; Vol. NA:NA.
21. Simhandl C, Meszaros K, Denk E, Thau K, Topitz A. Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie 1996;41(5):317.
22. Svestka J, Ceskova E, Rysanek R, Nahunek K. Controlled cross-over comparison of carbamazepine with perphenazine in schizophrenic psychoses. Activitas Nervosa Superior 1989;31(4):276-7.
23. Arana GW. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? 138th Annual Meeting of the American Psychiatric Association (1985, Dallas, Texas). American Journal of Psychiatry 1986;143(5):650-1.
24. Azorin JM, Samuelian JC, Pringuey D, Donnet A. Place of carbamazepine in the treatment of endogenous psychoses: Results of an open trial [Place de la carbamazepine dans le traitement des psychoses endogenes: Resultats d'une etude ouverte]. Encephale 1986;12(3):115-9.
25. Ballenger JC, Post RM. Carbamazepine in alcohol and withdrawal syndromes and schizophrenic psychoses. Psychopharmacology Bulletin 1984;20:572-84.
26. Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. International Clinical Psychopharmacology 1996;11(s2):67-71.
27. Bellaire W, Demisch K, Stoll K-D. Carbamazepine vs. lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses [Carbamazepin vs. Lithium. Einsatz in der Prophylaxe rezidivierender affektiver und schizoaffektiver Psychosen]. Münchner Medizinische Wochenschrift 1990;132:82-6.
28. Birkhimer LJ, Curtis JL, Jann MW. Use of carbamazepine in psychiatric disorders. Clinical Pharmacology 1985;4(4):425-34.
29. Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin 1991;27(2):103-6. [MEDLINE: 92021349;: PMID 1681560]
30. Botte L, Charles G. Clinical use of carbamazepine: Review from the literature and personal results [Utilisations cliniques de la carbamazepine: Revue de la litterature et resultats personnels]. Acta Psychiatrica Belgica 1988;88(3):181-94.
31. Cabrera J, Albrecht J, Muller-Oerlinghausen B. Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine. Nervenarzt 1987;58(4):245-9.
32. Cegalis JA, Possick SG. Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis. Yale Journal of Biology and Medicine 1985;58(4):327-36.
33. Chouinard G, Sultan S. Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases. Psychopharmacology Bulletin 1990;26(3):337.
34. Costa JF, Sramek J, Herrera JM. Hepatic reaction to carbamazepine. Journal of Clinical Psychopharmacology 1986;6(4):251-2.
35. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia Bulletin 2004;30(2):229-40. [MEDLINE: 15279042;: EMBASE 2004274059]
36. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971;12(12):335-40.
37. Dehing J. Studies on the psychotropic action of tegretol. Acta Neurologica Belgica 1968;68:895-905.
38. DenicoffKD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: A clinical practice survey. Journal of Clinical Psychiatry 1994;55(2):70.
39. de Vogelaer J. Carbamazepine in the treatment of psychotic and behavioral disorders. A pilot study. Acta Psychiatrica Belgica 1981;81:532-41.
40. Elphick M. An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. British Journal of Psychiatry 1985;147:198-200.
41. Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long-term response to carbamazepine: A retrospective study. Journal of Clinical Psychopharmacology 1988;8(2):130-2.
42. Gadow KD. Pediatric psychopharmacotherapy: A review of recent research. Journal of Child Psychology and Psychiatry and Allied Disciplines 1992;33(1):153-95.
43. Galletly CA, Tsourtos G. Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia. Annals of Clinical Psychiatry 1997;9(2):77-80.
44. Ginestet D, Ghanem T, Slama M. The variety of indications for carbamazepine. Revue du Praticien Medecine Generale 1996;10(336):11.
45. Goncalves N, Stoll KD. A controlled double-blind trial of carbamazepine in manic illness [Carbamazepin bei manischen Syndromen. Eine kontrollierte Doppelblind-Studie]. Nervenarzt 1985;56(1):43-7.
46. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR. Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. European Archives of Psychiatry and Clinical Neuroscience 1997;247(1):42-50.
47. Hakola HA, Laulumaa VA. Carbamazepine in treatment of violent schizophrenics. Lancet 1982;1(8285):1358.
48. Hermle L, Spitzer M. Succesful desensitization of a patient with schizoaffective psychosis and carbamazepin allergy. Nervenarzt 1993;64(3):208.
49. Heh CW, Sramek J, Herrera J, Costa J. Exacerbation of psychosis after discontinuation of carbamazepine treatment. American Journal of Psychiatry 1988;145(7):878-9.
50. Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intelligence & Clinical Pharmacy 1987;21(4):355-8.
51. Ivkovi M, Damjanovi A, Marinkovi D, Paunovi RV. Carbamazepine for acute psychosis with EEG abnormalities. Military-Medical and Pharmaceutical Review 2004;61(4):399-403.
52. Iwahashi K, Miyatake R, Suwaki H, Hosokawa K. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clinical Neuropharmacology 1995;18(3):233-6.
53. Iwahashi K. Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change [see comments]. Clinical Neuropharmacology 1996;19(3):267-70.
54. Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, et al. Effects of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology 1985;5(2):106-9.
55. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin 1995;21(4):607-19.
56. Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology 1990;10(1):54-7.
57. Karper LP, Seibyl JP, Krystal JH. Valproate management of psychosis in a patient with carbamazepine-induced hyponatremia. Journal of Clinical Psychopharmacology 1992;12(2):137-9.
58. Keck PE, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. Journal of Clinical Psychiatry 1996;57(s9):41-8.
59. Kessler AJ, Barklage NE, Jefferson JW. Mood disorders in the psychoneurologic borderland: Three cases of responsiveness to carbamazepine. 29th Annual Meeting of the International Psychiatric Research Society (1987, Madison, Wisconsin). American Journal of Psychiatry 1989;146(1):81-3.
60. Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry 1985;20(2):219-22.
61. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Archives of General Psychiatry 1984;41(2):165-70.
62. Kraft AM, Hassenfeld IN, Zarr M. Response to functional hallucinations to carbamazepine. American Journal of Psychiatry 1984;141(8):1018.
63. Lambert PA, Venaud G. Use of valpromide in psychiatric therapeutics. Encephale 1987;13(6):367-73. [CN-00477270]
64. Lapensee MA. A review of schizoaffective disorder: II. Somatic treatment. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie 1992;37(5):347.
65. Lenzi A, Lazzerini F, Grossi E, Massimetti G, Placidi GF. Use of carbamazepine in acute psychosis: A controlled study. Journal of International Medical Research 1986;14(2):78-84.
66. Llorca PM, Wolf MA, Lancon C, Bougerol T. Adjuvant drugs for use in patients under neuroleptics. Annales de Psychiatrie 1992;7(4):195.
67. Luchins DJ. Carbamazepine for the violent psychiatric patient. Lancet 1983;1(8327):766.
68. Luchins DJ. Carbamazepine in violent nonepileptic schizophrenics. Psychopharmacology Bulletin 1984;20(3):569-571.
69. Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. American Journal of Psychiatry 1984;141(5):687-8.
70. Makaric G, Folnegovic-Smalc V, Folnegovic Z, Imica N. Agitation in acute episode of schizophrenia: carbamazepine treatment in combination with haloperidol versus combined neuroleptics. Schizophrenia Research 2000;41(1):210. [MEDLINE: 1999367069]
71. McAllister TW. Carbamazepine in mixed frontal lobe and psychiatric disorders. Journal of Clinical Psychiatry 1985;46(9):393-4.
72. McKee RW, Larkin JG, Brodie MJ. Acute psychosis with carbamazepine and sodium valproate. Lancet 1989;1(8630):167.
73. Meltzer HY. Novel approaches to the pharmacotherapy of schizophrenia. Drug Development Research 1986;9(1):23-40.
74. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992;18(3):515-42.
75. Meshel E, Denber HC. Double-blind study of tybamate in psychotic patients. Diseases of the Nervous System 1967;28(5):311-3. [MEDLINE: 67165839;: PMID 5338174]
76. Meshel E, Denber HC. The use of tybamate in psychotic patients. (A further double blind study). Diseases of the Nervous System 1968;29(4):243-5. [MEDLINE: 68271597;: PMID 4870945]
77. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. British Journal of Clinical Pharmacology 2000;49 (suppl I):65S-70S.
78. Miller MJ, Shettel R, Fiedler HT. Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines. Psychosomatics 1965;6(5):340-2. [MEDLINE: 66013834;: PMID 5319246]
79. Miodownik C, Cohen H, Kotler M, Lerner V. Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah 2003;142(8-9):592-6, 647. [MEDLINE: 14518160;: EMBASE 2003374828; CN-00440574.]
80. Mokrusch T, Negele J, Kaschka WP. New aspects in the prophylaxis of affective and schizoaffective psychoses. Fortschritte der Medizin 1987;105(1):30-4.
81. Moller HJ, Kissling W, Riehl T, Bauml J. Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry 1989;13(1-2):127-36.
82. Möller H. Treatment of schizophrenia. State of the art. European Archives of Psychiatry and Clinical Neuroscience 1996;246(5):229.
83. Morinigo A, Mateo I, Martin J, Noval D, Gonzalez S. Efectos terapeuticos del valproato sodico y la carbamacepina en la mania. Psiquis 1992;13(8):335-8.
84. Mosca LD//Licciardo JP//Coppola JL. A double-blind carbamazepine-controlled efficacy and safety study of valproate in impulsivity and violence. 11th Congress of The European College of Neuropsychopharmacology; Oct 31-Nov 4, Paris, France. 1998. [MEDLINE: CONFERENCE ABSTRACT]
85. Munetz MR, Schulz SC, Bellin M, Harty I. Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Development Research 1989;16(1):79-83. [MEDLINE: 83197879;: PMID 6342171]
86. Nasser D, Thomas B. Anticonvulsant treatment of psychoses. Australian and New Zealand Journal of Psychiatry 1990;24(2):164.
87. Nelson JC. Combined treatment strategies in psychiatry. Journal of Clinical Psychiatry 1993;54(s9):42.
88. Neppe VM. Carbamazepine in nonresponsive psychosis. Journal of Clinical Psychiatry 1988;49(s):22-8.
89. Neppe VM, Tucker GJ, Wilensky AJ. Fundamentals of carbamazepine use in neuropsychiatry. Journal of Clinical Psychiatry 1988;49(s):4-6.
90. Neppe VM. Carbamazepine for withdrawal pseudohallucinations. American Journal of Psychiatry 1988;145(12):1605.
91. Neppe VM, Bowman BR, Sawchuk KS. Carbamazepine for atypical psychosis with episodic hostility. Journal of Nervous and Mental Disease 1991;179(7):439-41.
92. Nijdam JR, Doorschot CH, van Bavel LP, Loonen AJ. A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients. Pharmacopsychiatry 1992;25(3):145-9. [MEDLINE: 92342659]
93. Ohlmeier MD, Jahn K, Wilhelm-Gossling C, Godecke-Koch T, Hoffmann J, Seifert J, et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology 2007;55(2):81-8. [MEDLINE: 17570951]
94. Okuma T, Yamashita I, Takahashi R, Itoh H. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatrica Scandinavica 1989;80(3):250-9.
95. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al. Comparison of the therapeutic effect of carbamazepine and placebo in schizophrenia and atypical psychosis by double blind controlled study. Rinsho Hyoka 1988;16(2):327-73.
96. Okuma T, Yamashita I, Takahashi R, Itoh H. Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacopsychiatry 1989;22(2):47-53.
97. Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatric Services 1998;49:812-5.
98. Ortega SHA, Jasso A, Cecena G, Hernandez ACA. Validity and reproductivity of a scale for measuring neuroleptic-induced extrapyramidal symptoms [La validez y la reproducibilidad de dos escalas para evaluar los sintomas extrapiramidales inducidos por neurolepticos]. Salud Mental 1991;14(3):1-5.
99. Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, et al. Interaction between carbamazepine and bromperidol. European Journal of Clinical Pharmacology 1997;52(3):219.
100. Pantelis C, Barnes TR. Drug strategies and treatment-resistant schizophrenia. Australian and New Zealand Journal of Psychiatry 1996;30(1):20-37.
101. Panu H, Hakola A, Laulumaa VA. Carbamazepine in violent schizophrenics. In: Emrich HM, Okuma T editor(s). Anticonvulsants in Affective Disorders. Amsterdam: Elsevier, 1984:204-7.
102. Placidi GF, Lenzi A, Lazzerini F, Cassano GB. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Journal of Clinical Psychiatry 1986;47(10):490-4.
103. Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano GB, Grossi E. Long term-double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results. In: Emrich HM, Okuma T editor(s). Anticonvulsants in Affective Disorders. Amsterdam: Elsevier, 1984:188-97.
104. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics: A case report. Psychopharmacology 1994;116(1):115-6.
105. Rankel HW, Rankel LE. Carbamazepine in the treatment of catatonia. American Journal of Psychiatry 1988;145(3):361-2.
106. Rittmannsberger H. Carbamazepine in the treatment of psychiatric illness: Effects and side effects. Wiener Medizinische Wochenschrift 1990;140(15):398.
107. Scher M, Neppe V. Carbamazepine adjunct for nonresponsive psychosis with prior hallucinogenic abuse. Journal of Nervous and Mental Disease 1989;177(12):755.
108. Schulz SC, Conley RR, Kahn EM, et al. Nonresponders to neuroleptics: a distinct subtype. Schizophrenia: scientific progress. New York: Oxford University Press, Date of publication and page numbers not indicated.
109. Schulz SC, Kahn EM, Baker RW, et al. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. The Neuroleptic-Nonresponsive Patient: Characterization and Treatment. Washington DC: American Psychiatric Press, 1990:111-36.
110. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review. Journal of Psychiatry and Neuroscience 1992;17(1):1-14.
111. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. British Journal of Psychiatry 1993;163(s22):22-78.
112. Heh CW, Potkin SG, Pickar D, Costa J, Herrera J, Sramek J, et al. Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics. Biological Psychiatry 1989;25(5):639-41.
113. Herrera J, Sramek J, Costa C, Heh C, Wernberg C. An evaluation of carbamazepine (Tegretol) in chronic treatment-refractory schizophrenia. Proceedings of the 95th Annual Conference of the American Psychiatric Association. 1987:588-9.
114. Sramek J, Herrera J, Costa J, Heh C, Tran Johnson T, Simpson G. A carbamazepine trial in chronic, treatment-refractory schizophrenia. American Journal of Psychiatry 1988;145(6):748-50.
115. Tran-Johnson T, Sramek JJ, Walker NR, Heh CD, Costa JF, Herrera JM. Effects of carbamazepine on serum calcium in schizophrenia. DICP 1989;23(12):1034.
116. Sugerman AA, Hyams L. Electroencephalographic effects of adrenochrome semicarbazone in schizophrenia: quantitative amplitude analysis. Research Communications in Chemical Pathology and Pharmacology 1970;1(1):86-98. [MEDLINE: 72091267;: PMID 4944698]
117. Svestka J, Nahunek K, Ceskova E, Korbicka J. Carbamazepine prophylaxis of affective psychoses: Intraindividual comparison with lithium carbonate. 27th Annual Psychopharmacology Meeting (1985, Jesenik, Czechoslovakia). Activitas Nervosa Superior 1985;27(4):261-2.
118. Svestka J, Nahunek K, Ceskova E. Carbamazepine in the treatment and prophylaxis of affective psychoses [Pouziti carbamazepinu v lecbe a profylaxi afektivnich psychoz]. Ceskoslovenska Psychiatrie 1988;84(3):145-55.
119. Tohen M, Castillo J, Pope HG, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. Journal of Clinical Psychopharmacology 1994;14(1):67.
120. Walden J, Von WJ, Berger M, Grunze H. Efficacy of antiepileptic drugs in the treatment of psychiatric diseases. EEG Labor 1996;18(1):32.
121. Wetterling T. Open clinical trial of carbamazepine in chronic schizophrenic inpatients. Pharmacopsychiatry 1987;20(3):127-30.
122. Wunderlich HP, Grunes JU, Neumann J, Zahlten W. Carbamazepine (Finlepsin(TM)) for manicdepressive and schizophrenic diseases. Deutsche Gesundheitswesen 1983;38(35):1352-6.
123. Yassa R, Dupont D. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: A case report. Canadian Journal of Psychiatry 1983;28(7):566-8.
124. Kamisada M, Tateyama M, Nakano Y, Kawachi Y, Fujii Y, Tanoue A, et al. Comparison of the clinical effects of lithium carbonate and carbamazepine on excited schizophrenics. Psychopharmacology 1988;96(Suppl):348. [MEDLINE: 72091267;: PMID 4944698]
125. Lee MS, Choi BH, Kim SH. Combined use of carbamazepine and valproic acid in negative symptom schizophrenia. 9th Congress of the European College of Neuropsychopharmacology; September 21-25, Amsterdam, The Netherlands. 1996. [MEDLINE: 98249354]
126. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
127. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry 1982;39:784-8.
128. Andreasen NC. The scale for assessment of positive symptoms. University of Iowa 1984.
129. Beg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.
130. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
131. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
132. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
133. Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database of Systematic Reviews 2001, Issue Issue 3. [DOI: 10.1002/14651858.CD000234]
134. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
135. Dardennes R, Even C, Bange F, Heim A. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder: a meta-analysis. British Journal of Psychiatry 1995;166:378-81.
136. Davey Smith G, Egger M. Meta-analysis: Unresolved issues and future developments. BMJ 1998;16:221-5.
137. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
138. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
139. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD006391.pub2]
140. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
141. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
142. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
143. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174]
144. GRADE Working Group. GRADE Profiler. 3.2. GRADE Working Group, 2004.
145. Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology 1995;47:1189-96.
146. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
147. Guy W. ECDEU assessment manual for psychopharmacology-revised. Washington, D.C: DHEW. National Institute of Mental Health 1976.
148. Hamilton M. A rating scale of depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
149. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
150. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
151. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
152. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
153. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
154. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
155. Kay SR, Fiszbein A. The positive and negative symptome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-75.
156. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
157. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
158. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
159. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD003834.pub2]
160. Lorr M, McNair DM, Klett CJ, Lasky JJ. Evidence of ten psychotic symptoms. Journal of Consulting Psychology 1962;26:185.
161. Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
162. Marwaha S, Johnson S. Schizophrenia and employment ? A review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
163. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;258:1987-91.
164. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
165. Pate LA. Carbamazepine in treatment of the violent psychotic patients. Jefferson Journal of Psychiatry 1986;4(1):28-36.
166. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
167. Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
168. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
169. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
170. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD000076.pub2;: CD000076]
171. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8.
172. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
173. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
174. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
175. Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence?. Journal of Clinical Psychiatry 2002;63(3):218-24.
176. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD001258]
177. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001258.pub2]